Shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) traded down 0% on Monday . The company traded as low as $2.06 and last traded at $2.38. 382,100 shares changed hands during trading, a decline of 72% from the average session volume of 1,371,057 shares. The stock had previously closed at $2.38.

A number of analysts recently weighed in on the stock. Zacks Investment Research upgraded shares of HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a report on Tuesday, July 18th. ValuEngine upgraded shares of HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a report on Monday, July 17th. Finally, HC Wainwright set a $6.00 target price on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a report on Wednesday, August 9th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $6.17.

In related news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total value of $2,081,161.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 1,661,889 shares of company stock valued at $3,077,980 in the last ninety days. Company insiders own 7.60% of the company’s stock.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. increased its position in HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 135,234 shares of the medical research company’s stock after purchasing an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 at the end of the most recent reporting period. 19.99% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “HTG Molecular Diagnostics, Inc. (HTGM) Stock Price Down 0%” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://theolympiareport.com/2017/11/13/htg-molecular-diagnostics-inc-htgm-stock-price-down-0.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.